Use of methotrexate in undifferentiated arthritis

CER4030
2010 Vol.28, N°5 ,Suppl.61
PI 0117, PF 0121
Review

Free to view
(click on article PDF icon to read the article)

PMID: 21044444 [PubMed]

Received: 31/07/2010
Accepted : 07/09/2010
In Press: 28/10/2010
Published: 28/10/2010

Abstract

The prognosis of patients with undifferentiated arthritis (UA) may vary from self-limited to severe destructive rheumatoid arthritis (RA). Based on the chance that these patients will develop RA and based on the safety profile of a course of methotrexate for 30–90 days, many clinicians consider using methotrexate in this patient category using the `n of 1` trial principle. During the last few years, more data on interventions in UA have become available that provide guidance in the prescription of drugs to UA patients.